Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome

14 Sept 2017

Abstract excerpt

Pancreatic ductal adenocarcinoma (PDAC) is a tumor with a poor prognosis, and no targeted therapy is currently available. The aim of the present study was to investigate the prognostic significance of the expression of V‑Ki‑ras2 Κirsten rat sarcoma viral oncogene homolog (KRAS), downstream signaling pathway genes and the association with clinical characteristics in PDAC patients undergoing radical surgery....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Pancreatic and Hepatic Oncology Research
Share to Pancreatitis Pathology and Treatment
Share to TGF-β signaling in diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29113235
DOI: 10.3892/ol.2017.6946

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcomePMID 29113235Read ↗

Crosstalk between KRAS and miRNAs in pancreatic cancer: Opportunities for its diagnosis, prognosis and therapeutic intervention (Review).Semantic proximity Read ↗

KRAS Pathway-based Therapeutic Approaches in Pancreatic Cancer.Semantic proximity Read ↗

Critical role of KRAS mutation in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Moving Towards Dawn: KRas Signaling and Treatment in Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

KRAS: the Achilles' heel of pancreas cancer biology.Semantic proximity Read ↗

The KRAS signaling pathway's impact on the characteristics of pancreatic cancer cells.Semantic proximity Read ↗

KRAS mutation status is associated with specific pattern of genes expression in pancreatic adenocarcinoma.Semantic proximity Read ↗

Clinicopathological and molecular characterization of KRAS wild‐type pancreatic ductal adenocarcinomas reveals precursor lesions with oncogenic mutations and fusions in RAS pathway genesSemantic proximity Read ↗

KRAS-dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS InhibitorsSemantic proximity Read ↗

Key Considerations for Targeting KRAS in Pancreatic Cancer: Potential Impact on the Treatment Paradigm.Semantic proximity Read ↗

KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of TherapySemantic proximity Read ↗

Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.